Brief: Insomnia Treatment Study Using Medipharm Labs Cbd50 Product To Proceed To Phase 2 With Health Canada Consent
31/08/2021 12:29
Aug 31 (Reuters) - Medipharm Labs Corp LABS.TO :
* INSOMNIA TREATMENT STUDY USING MEDIPHARM LABS CBD50
PRODUCT TO
PROCEED TO PHASE 2 WITH HEALTH CANADA CONSENT
Source text for Eikon: ID:nGNX9m7yJN
Further company coverage: LABS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medipharm Labs
See all newsCanada's MediPharm Labs Q2 revenue rises 11% on international growth
Brief: MediPharm Labs Q2 Revenue CAD 10 Million
Canada's MediPharm Labs reports positive Q1 adjusted EBITDA
Canada's MediPharm Labs FY revenue rises 8% on international sales
Brief: Medipharm Labs Reports Full Year & Fourth Quarter 2025 Results With Over 40% Annual Growth In International Medical Revenue